Stockreport

Vaxcyte Announces Pricing of $750 Million Public Offering

Vaxcyte, Inc.  (PCVX) 
PDF SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to p [Read more]